האיחוד האירופי - אנגלית - myHealthbox

takeda austria gmbh - human fibrinogen / human thrombin - sealant matrix - 5.5 mg human fibrinogen and 2.0 iu human thrombin per cm² - hemostasis, surgical - local haemostatics - indicated in adults for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing, and for suture support in vascular surgery where standard techniques are insufficient

האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

corza medical gmbh - human fibrinogen, human thrombin - hemostasis, surgical - antihemorrhagics - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.1).

האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

mallinckrodt pharmaceuticals ireland limited - human fibrinogen, human thrombin - hemostasis, surgical - antihemorrhagics - supportive treatment where standard surgical techniques are insufficient for improvement of haemostasis.raplixa must be used in combination with an approved gelatin sponge.raplixa is indicated in adults over 18 years of age.

האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

instituto grifols, s.a. - human fibrinogen, human thrombin - hemostasis, surgical - antihemorrhagics - supportive treatment in adults where standard surgical techniques are insufficient:for improvement of haemostasisas suture support in vascular surgery

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd - human thrombin, quantity: 800 iu - solution - excipient ingredients: water for injections; mannitol; sodium acetate; albumin; calcium chloride dihydrate; tributyl phosphate; octoxinol 9 - as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. as suture support for haemostasis in large vessel vascular surgery. for suture line sealing in dura mater closure.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd - human thrombin, quantity: 4000 iu - solution - excipient ingredients: mannitol; calcium chloride dihydrate; water for injections; sodium acetate; albumin; tributyl phosphate; octoxinol 9 - ? as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. ? as suture support for haemostasis in large vessel vascular surgery. ? for suture line sealing in dura mater closure.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd - human thrombin, quantity: 1600 iu - solution - excipient ingredients: water for injections; mannitol; sodium acetate; albumin; calcium chloride dihydrate; tributyl phosphate; octoxinol 9 - ? as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. ? as suture support for haemostasis in large vessel vascular surgery. ? for suture line sealing in dura mater closure.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

baxalta us inc. - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 90 mg in 1 ml - tisseel is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. tisseel is effective in heparinized patients. tisseel is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies. do not inject tisseel directly into the circulatory system or into highly vascularized tissue. intravascular application of tisseel can lead to intravascular coagulation, can result in life-threatening thromboembolic events, and can increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients (see warnings and precautions(5.3) and adverse reactions (6.2)).   do not use tisseel in individuals with a known hypersensitivity to aprotinin  (see warnings and pre

ארצות הברית - אנגלית - NLM (National Library of Medicine)

baxalta us inc. - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 90 mg in 1 ml - tisseel is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. tisseel is effective in heparinized patients. tisseel is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies. do not inject tisseel directly into the circulatory system or into highly vascularized tissue. intravascular application of tisseel can lead to intravascular coagulation, can result in life-threatening thromboembolic events, and can increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients (see warnings and precautions(5.3) and adverse reactions (6.2)).   do not use tisseel in individuals with a known hypersensitivity to aprotinin  (see warnings and pre

ארצות הברית - אנגלית - NLM (National Library of Medicine)

ethicon inc - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 85 mg in 1 ml - evicel® fibrin sealant (human) is indicated as an adjunct to hemostasis for use in patients undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical. do not use evicel® : - directly into the circulatory system. intravascular application of evicel® may result in life-threatening thromboembolic events [see warnings and precautions, (5.1) and adverse reactions, (6.2)]. - in individuals known to have anaphylactic or severe systemic reaction to human blood products [see adverse reactions (6.2)]. - for brisk arterial bleeding. - for spraying in endoscopic or laparoscopic procedures in those instances where the minimum recommended distance from the applicator tip to the target site cannot be ensured. [see dosage and administration (2.3)]. risk summary there are no data with evicel® use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with evicel® . it is not known whether